Publications

5600 Results

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)

Authors
M Dickler;WT Barry;CT Cirrincione;M Ellis;M Moynahan;H Rugo;B Schneider;D Tripathy;C Hudis;E Winer
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 501); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;K Guthrie;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS4142); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), TIPS, poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310

Intergroup pilot study of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by capecitabine-based chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101

Authors
MHG Katz;Q Shi;SA Ahmad;J Herman;R Marsh;E Collisson;L Schwartz;H Kindler;AM Lowy;AP Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021101

SWOG S0809: A phase II intergroup trial of adjuvant capecitabine/gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma

Authors
E Ben-Josef;K Guthrie;A El-Khoueiry;C Corless;M Zalupski;A Lowy;CR Thomas;SR Alberts;L Dawson;K Micetich;M Thomas;A Siegel;C Blanke
Journal / Conference
Journal of Clinical Oncology Aug 20;33(24):2617-2622
Year
2015
Research Committee(s)
Gastrointestinal
PMID
PMID25964250
PMC
PMC4534524
Study Number(s)
S0809

Safety and tolerability of the combination of ATRA + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): initial report of the SWOG/Alliance/ECOG S0535 trial (NCT00551460)

Authors
J Lancet;M Othus;R Komrokji;S Coutre;D DeAngelo;M Tallman;M Litzow;F Appelbaum
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 7016); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0535

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT00658814)

Authors
S Nand;N Achille;M Othus;K Phelan;S Zhang;K Cooper;J Godwin;F Appelbaum;J Radich;H Erba;N Zeleznik-Le
Journal / Conference
Journal of Clinical Oncology J Clin Oncol 33:5s (suppl; abstr 7060); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0703

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac), A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial - NCT01349881

Authors
J Zell;J Unger;G Anderson;E Cook;J Krouse;P Lance;L Minasian;L Ford;P Brown
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS3627); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0820

SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/K mutant melanoma

Authors
A Algazi;M Othus;A Daud;J Mehnert;C Lao;R Kudchadkar;K Grossmann;R Lo;J Moon;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9093); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1320

SWOG S1404: A phase III randomized trial comparing high dose interferon to MK-3475 (pembrolizumab) in patients with high risk resected melanoma

Authors
K Grossmann;M Othus;A Tarhini;S Patel;J Moon;V Sondak;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9085); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1404

SWOG S9005: double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma

Authors
H Ji;C Rankin;S Grungerg;J Ahmadi;L Feun;R Fredericks;C Russell;F Kabbinavar;K Stelzer;A Schott;C Verschraegen
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr e17084); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), publication only;
Year
2015
Research Committee(s)
Brain
Study Number(s)
SWOG-9005